U.S. markets close in 14 minutes
  • S&P 500

    4,064.38
    -12.19 (-0.30%)
     
  • Dow 30

    34,370.97
    -24.04 (-0.07%)
     
  • Nasdaq

    11,463.78
    -18.67 (-0.16%)
     
  • Russell 2000

    1,895.97
    +14.30 (+0.76%)
     
  • Crude Oil

    80.23
    -0.99 (-1.22%)
     
  • Gold

    1,812.90
    -2.30 (-0.13%)
     
  • Silver

    23.45
    +0.61 (+2.67%)
     
  • EUR/USD

    1.0537
    +0.0009 (+0.08%)
     
  • 10-Yr Bond

    3.5060
    -0.0230 (-0.65%)
     
  • GBP/USD

    1.2284
    +0.0027 (+0.22%)
     
  • USD/JPY

    134.2710
    -1.0350 (-0.76%)
     
  • BTC-USD

    17,004.27
    +66.17 (+0.39%)
     
  • CMC Crypto 200

    404.05
    +2.63 (+0.66%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

Repligen Beefs Up Process Analytics Portfolio With DRS Daylight Solutions Pact

  • Repligen Corporation (NASDAQ: RGEN) entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market.

  • Through this agreement, Repligen will assume responsibility for the commercialization of Culpeo and the development of future products and technologies in partnership with DRS Daylight Solutions.

  • Also read: Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says.

  • Both companies will focus on expanding the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) based solutions and integrating these solutions into Repligen Chromatography and Filtration systems to expand their presence in the Process Analytics Technology (PAT) segment.

  • Daylight's patented QCL-IR technology measures higher-order protein and nucleic acid structure, facilitating the measurement of protein aggregation, concentration, nucleic acid content, and other critical attributes in biological manufacturing processes.

  • DRS Daylight Solutions entered the bioprocessing market in 2018 with its ground-breaking Culpeo instrument.

  • Price Action: RGEN shares are down 5.43% at $212.97 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.